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High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous
carcinoma of the breast
Aims: Low-grade adenosquamous carcinoma of the
breast (LGASC) is a rare variant of metaplastic carci-
noma characterised by a favourable outcome and histo-
logically composed of glandular and squamous
elements in a spindle cell background typically associ-
ated with a lymphocytic stromal reaction. Because of its
rarity, the immunophenotypic and genetic profile of
LGASC has not been sufficiently characterised. The aim
of this study was to gain insights into the molecular and
phenotypic characteristics of LGASC.
Methods and results: We reviewed the clinical and
morphological features and detailed the immunohisto-
chemical characteristics of a retrospective series of 13
LGASCs. Targeted sequencing of 50 genes was per-
formed in 10 of 13 cases. Identified mutations were
further assessed by Sanger sequencing in a validation
series of 11 additional cases. All tumours showed a
triple-negative immunophenotype, expressed ‘basal’
keratins, showed variable levels of epidermal growth
factor receptor expression, and did not express
androgen receptor. Sequencing analysis of the
screening set of LGASCs revealed a high rate (seven
of 10 cases) of PIK3CA mutations, whereas no TP53
mutations were found. All PIK3CA mutations were
missense mutations located either in exon 20
(n = 6) or in exon 9 (n = 1). The global PIK3CA
mutation rate, including the validation series, was
52% (11 of 21 cases). No disease recurrences were
observed. [Correction added on 11 June 2018, after
first online publication: The percentage of mutation
rate was corrected to 52%]
Conclusions: Our results indicate that LGASC of the
breast is a low-grade triple-negative breast cancer
that harbours a basal-like phenotype with no andro-
gen receptor expression, and shows a high rate of
PIK3CA mutations but no TP53 mutations.
Keywords: androgen receptor, breast cancer, low-grade adenosquamous carcinoma, metaplastic carcinoma,
PIK3CA mutations
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Introduction
Low-grade adenosquamous carcinomas of the breast
(LGASCs) represent a rare histological type of invasive
breast cancer that has been included in the latest edi-
tion of the World Health Organisation classification,1
as part of the spectrum of metaplastic carcinomas of
the breast. They feature well-developed gland/tubule
formation intimately admixed with solid nests of
squamous cells in a spindle cell background. Rosen
and Ernsberger2 emphasised that, despite the pres-
ence of metaplastic elements, these tumours show a
low-grade histological pattern.
Typically, the carcinomatous component is charac-
terised by small glandular structures with rounded
rather than angulated contours, and solid cords of
epithelial cells that may contain squamous cells,
squamous pearls, or squamous cyst formation. The
epithelial structures of adenosquamous carcinomas
are often dispersed in a highly cellular spindle cell
background. These spindle cells appear to merge with
the epithelial cells and, in some cases, spindle cell
metaplasia may be identified. Some authorities have
suggested that the spindle cell background may be
considered as part of the neoplastic component.3
However, it may sometimes be difficult to distinguish
between spindle cell metaplasia and ordinary
stroma,4,5 and this fusiform background may be chal-
lenging to interpret in core needle biopsy specimens.
In agreement with their low-grade morphological fea-
tures, the majority of LGASCs show an excellent
prognosis with a low incidence of lymph node
metastasis.6 A proportion of cases, however, can
behave in a locally aggressive manner.6
Although several case reports and relatively small
cohorts have been reported over the years, LGASC
remains poorly defined in terms of phenotype; in
addition, its genetic profile is yet to be established.3,6–
16 The immunohistochemical studies published to date
have described LGASC as part of the triple-negative
breast cancer (TNBC) spectrum.1,6,17,18
A genome-wide characterisation of copy number
alterations has been performed on two cases, one of
which showed a complex profile of copy number
changes encompassing focal amplifications.3 A thor-
ough genomic characterisation of metaplastic carci-
nomas has been recently provided,19 but, regrettably,
LGASCs were not present in the cohort.
To gain greater insights into the specific biological
characteristics of LGASC, in this study we report a
detailed morphological and immunophenotypic analy-
sis of 13 cases and the first characterisation of the
genomic landscape of LGASC by use of a targeted
panel of genuine cancer genes.
Materials and methods
C A S E S
We retrospectively retrieved 13 LGASCs diagnosed at
Institut Curie (Paris and Saint Cloud) and at Centre
Francois Baclesse (Caen) between 1999 and 2013.
These carcinomas were originally registered as either
‘adenosquamous’ or ‘metaplastic’ carcinomas. Sam-
ples were anonymised before analysis. Ethical
approval from the Institutional Review Board (Institut
Curie breast cancer study group: IRB 03/14) was
obtained for the use of all specimens. Clinical data on
treatment and follow-up were obtained from the Insti-
tut Curie electronic medical records.
A second independent cohort of 11 LGASCs that
served as a validation series was obtained from the
Centre Georges Francois Leclerc in Dijon, Centre Jean
Perrin in Clermont-Ferrand, and Centre Leon-Berard
in Lyon.
M O R P H O L O G I C A L A N A L Y S I S
Histopathological review was performed by two expe-
rienced breast pathologists (A.V.S. and G.B.) for the
purpose of subtyping and grading (using the Elston–
Ellis grading system).20 Specific histological features
commonly seen in LGASC, such as degree of glandu-
lar, squamous and spindle cell differentiation, were
assessed, and tumours were classified according to
the predominant component (glandular, squamous,
and spindle cell). In addition, stromal characteristics,
including the presence/degree of lymphoid aggre-
gates, were recorded. The respective proportions of
glandular and squamous tumour cells and the spindle
cell component, lymphoid stromal cells and associated
normal glands within the tumour were determined.
The presence of lymphovascular invasion and lymph
node metastasis was also recorded.
I M M U N O H I S T O C H E M I S T R Y
Three-micrometre-thick formalin-fixed paraffin-
embedded (FFPE) sections were mounted on silane-
coated slides. Immunohistochemical staining was
performed with 16 different antibodies directed
against oestrogen receptor (ER), progesterone receptor
(PR), androgen receptor (AR), human epidermal
growth factor receptor 2 (HER2), Ki67, epidermal
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growth factor receptor (EGFR), p63, cytokeratin (CK)
5/6, CK7, CK14, CK8/18, a-smooth muscle actin, E-
cadherin, CD117, PTEN, and EZH2. Details of anti-
body sources, dilutions and antigen retrieval methods
are summarised in Table S1. Positive and negative
controls (omission of the primary antibody and IgG-
matched serum) were utilised.
All markers were scored (percentage of positive
tumour cells) separately in the glandular, squamous
and spindle cell components of the tumours. ER, PR
and HER2 were evaluated according to the current
American Society of Clinical Oncology/College of
American Pathologists guidelines.21,22 The positive
cut-off for expression of all other markers was 10%.
Markers were characterised according to the highest
percentage of positive cells within each component.
M A C R O D I S S E C T I O N A N D D N A E X T R A C T I O N
All tumours were macroscopically dissected to enrich
for tumour cell content, by taking out normal breast tis-
sue and any areas of fibrocystic changes and intraduc-
tal papillomas. Macrodissection was performed with a
sterile scalpel from three consecutive 6-lm-thick sec-
tions of FFPE samples after deparaffinisation, guided by
the microscopic limits of the tumour on the haema-
toxylin and eosin-stained section. DNA was extracted
with the NucleoSpin 8 tissue Kit (Macherey Nagel,
D€uren, Germany), according to the manufacturer’s rec-
ommendations. The DNA level was measured with the
Qubit 2.0 fluorometer assay according to the manufac-
turer’s instructions (Life Technologies, Thermo Fisher
Scientific, Waltham, MA, USA). A KRAS polymerase
chain reaction (PCR) was performed with LightMix Kit
Kras to assess DNA quality. Following DNA quantifica-
tion and quality assessment, three of 13 cases were
withdrawn because of lack of dissected material (case
6) or excessively low DNA levels (cases 2 and 4).
T A R G E T E D M A S S I V E P A R A L L E L S E Q U E N C I N G
( M P S )
Given that only FFPE material was available, we
focused on mutations affecting known oncogenes and
tumour suppressor genes in human cancers. For this
purpose, targeted sequencing was performed with the
Ion Ampliseq Cancer Hotspot panel v2 in conjunction
with the Ampliseq library kit v2.0 and the Ion Tor-
rent Personal Genome Machine (PGM) Analyzer (Life
Technologies, Carlsbad, CA, USA). According to the
manufacturer’s instructions, 10 ng of extracted DNA
was used to generate 207 amplicons surveying 2800
COSMIC mutations in 50 well-established oncogenes
and tumour suppressor genes that are frequently
mutated in different malignancies, including breast
cancer (summarised in Table S2).
Extremities of amplicons were partially digested,
and Ion adapters (Ion Xpress PCR barcode adapters;
Life Technologies), including one with a molecular
barcode, were ligated at both ends. After amplifica-
tion of the construction, the quality of the libraries
was checked on a BioAnalyzer (Agilent, Santa Clara,
CA, USA) and quantified with Qubit Technology (Life
Technologies). Template preparation was performed
with the Ion OneTouch System 2 with the Ion PGM
Template OT2 200 Kit (Life Technologies). Templates
were sequenced on the Ion Torrent PGM with an Ion
PGM Sequencing 200 Kit v2 and an Ion 318v2 Chip.
The overall quality of each run was evaluated on
the basis of the report generated by the Torrent Ser-
ver. At least 100 000 reads per sample were
required. A sample was considered to be valid only if
95% of targeted positions were covered at >1009,
according to the analysis performed by the variant
caller plugin of TORRENT SUITE (Life Technologies).
V A R I A N T C A L L I N G
Data from the PGM runs were initially processed with
the Ion Torrent platform-specific pipeline software
TORRENT SUITE to generate sequence reads, trim adapter
sequences, and filter and remove poor signal-profile
reads. Initial variant calling from the Ion AmpliSeq
sequencing data was generated by TORRENT SUITE v3.0
with a plug-in ‘variant caller’ program. For mutation
analyses, sequencing reads were aligned on the
human reference genome (hg19) by the use of TMAP
(Life Technologies). Variants were detected with
VARIANT CALLER (Life Technologies), and annotated by
use of the ANNOVAR pipeline.23 Variants were fil-
tered according to their frequency [>4% for single-
nucleotide variants (SNVs) and >10% for indels],
strand ratio (>0.2), and read coverage (>309 for
SNVs and >1009 for indels). The Bioinformatics plat-
form integrated the different molecular results in a
name-blinded technical report, which was then
discussed and interpreted by a pathologist and a
molecular biologist together (G.B. and I.B.). Align-
ments were verified visually with the Integrative
Genomics Viewer v.2.2 (Broad Institute).
S T A T I S T I C A L A N A L Y S I S
COSMIC (version 64) and the My Cancer Genome
database (http://www.mycancergenome.org/) were
used to assess recurring mutations in breast cancer.
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Statistical correlations were performed with GRAPHPAD
PRISM version 6 (GraphPad Software, La Jolla, CA,
USA).
V A L I D A T I O N O F M U T A T I O N S
Mutations identified in the 10 cases subjected to tar-
geted MPS were validated by Sanger sequencing
(LightCycler 480 Real-Time PCR system, kit PIK3CA,
Roche Molecular Systems, Indianapolis, IN, USA).
The frequency of PIK3CA mutations was further
explored by Sanger sequencing, including in the vali-
dation series of 11 LGASCs (Table S3).
Results
C L I N I C A L F E A T U R E S
The clinicopathological features of the cohort are sum-
marised in Table 1. All patients were female, and they
were predominantly of postmenopausal age. Tumour
size ranged from 3.5 mm to 70 mm (mean, 22 mm;
median, 15 mm). One case (case 8) had axillary lymph
node metastases showing a ductal morphology remi-
niscent of a previously diagnosed contralateral breast
carcinoma (Table 1), and showed ER and PR expres-
sion. Clinical follow-up (range, 3–17 years; mean,
7.5 years) did not reveal any recurrences.
H I S T O P A T H O L O G Y
As summarised in Table 2, all cases had varying
degrees of glandular, squamous and spindle cell com-
ponents (Figure 1).
The epithelial component was organised in small
tubules, cell clusters and cords with focal squamous
differentiation in a spindle cell background. Neoplastic
glands were elongated, ovoid, or compressed, and
some infiltrated in and around residual normal
glands. Spindle cells and stromal cells (fibroblasts and
lymphoid cells) intimately surrounded the epithelial
cell nests. Lymphocytic aggregates were present in all
tumours. Neither necrosis nor vascular invasion was
observed.
Case 3 showed a focal high-grade component, in
line with previous descriptions of progression from
low-grade adenosquamous carcinoma to high-grade
metaplastic carcinoma.2,24
I M M U N O P H E N O T Y P I C A N A L Y S I S
Immunohistochemistry results are summarised in
Figures 2 and 3 and detailed in Table S4. All
tumours were of the triple-negative phenotype (ER-
negative, PR-negative, and HER2-negative) and
lacked AR expression. The proliferation indices
assessed according to Ki67 ranged between 2% and
20% (mean, 11%; median, 10%). The immunophe-
notype was found to be relatively similar across the
various cases, depending on their predominant com-
ponent: glandular, squamous, or spindle cell
(Figure 2).
The glandular component was characterised by dif-
fuse (>50%) expression of CK7 and CK14, E-cadherin,
and EZH2. The squamous component expressed
CK14, E-cadherin, CK7, CK5/6, EZH2, p63, and
PTEN, whereas the spindle cell component expressed
SMA, PTEN and, to a lesser extent, EZH2. Some of
the spindle cells showed expression of CK5/6, CK14,
CK7, and p63.
M U T A T I O N F R E Q U E N C Y I N K N O W N C A N C E R
G E N E S
Mutations affecting the 50 genes included in the
targeted AmpliSeq Panel V2 are summarised in
Table 2 and detailed in Table S5. Ten breast
LGASC samples were analysed by MPS. A mean
1009 coverage of 90% with a mean read length
of 226 bp was obtained in the 10 FFPE samples.
The majority of the samples (seven of 10 cases,
70%) harboured missense PIK3CA mutations
affecting exon 20 (n = 6) or exon 9 (n = 1), and
corresponding to the kinase (H1047L and
H1047R) and helical (E542K) domains, respec-
tively. Two of the samples showing a PIK3CA
mutation also harboured mutations in GNAS and
KIT (cases 1 and 3, respectively). Co-occurrence of
CDKN2A and PTEN mutations was detected in one
other case (case 7). TP53 was sequenced in all
exons except exon 1, and no TP53 mutations were
identified.
Six of the seven PIK3CA mutations identified by
Ion Torrent sequencing analysis were subsequently
validated by Sanger sequencing in the index cases.
It should be noted that the PIK3CA mutation not
detected by Sanger sequencing showed an allele fre-
quency of 6.7% in the Ion Torrent sequencing
assay. To confirm the high rate of PIK3CA muta-
tions in this entity, we analysed an independent
series of 11 LGASCs and found four tumours (36%)
harbouring PIK3CA mutations in exon 20 (n = 2)
or exon 9 (n = 2) (Table S5B). The global PIK3CA
mutation rate, including screening and validation
series, accounted for 52% (11 of 21 cases)
(Table S5C).
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Discussion
In this study, we show that LGASC represents an
indolent form of TNBC with basal-like features char-
acterised by high rates of PIK3CA mutations and lack
of TP53 mutations. These data on LGASC provide
insights into the genomic landscape of metaplastic
breast cancer, and may help in the understanding of
the possible evolutionary pathways of low-grade
forms of TNBC, by representing a starting point for
future studies of putative precursors of LGASC and
other metaplastic carcinomas. These findings may
also be of help in the diagnostic setting, because,
although LGASC can be relatively easily recognised
on morphological grounds in surgical specimens, it
may be a challenging entity to be diagnosed on core
biopsy samples with respect to other fusiform prolifer-
ations, especially those of low grade.
LGASC is an unusual form of metaplastic carci-
noma featuring a variable admixture of well-formed
glands and solid cords of cells with squamous features
arranged in a haphazard, infiltrative pattern and typi-
cally showing relatively little cytological atypia and
low levels of proliferation, to the extent that differen-
tial diagnosis with radial scar (RS)/complex sclerosing
lesions (CSLs) can be challenging. The extension of
the lesion in a spindle cell background that can stand
for the presence of desmoplastic stroma and the pres-
ence of a triple-negative phenotype may represent
helpful features for the differential diagnosis.
So far, relatively small cohorts characterising this
entity have been reported, and almost exclusively at
the immunophenotypic level. In agreement with pre-
vious studies,6,18 all of the cases pertaining to our
series were of the triple-negative phenotype. In addi-
tion, AR expression was not observed. This is in con-
trast to the report of the large majority of metaplastic
carcinomas being AR-positive, except for squamous
cell carcinomas.25 We also confirmed in the epithelial
neoplastic component the consistent expression of
basal CKs and of markers usually expressed in normal
myoepithelial cells. In a subgroup of cases, a minor
proportion of the spindle cells also expressed p63,
CKs, and EZH2, which is a protein that is overex-
pressed in a wide range of solid tumour types, includ-
ing breast cancer.26 Taken together, these
preliminary observations may indirectly suggest that
the spindle cell background observed in LGASC could
be an integral part of the neoplastic process. This
hypothesis should be further explored in studies
aimed at analysing the molecular features of the dis-
tinct cell components of LGASCs. Interestingly Geyer
A B
C D
E F
Figure 1. Histological features of low-grade adenosquamous carcinomas of the breast (Hematoxylin-Eosin-Saffron). This entity is composed
of infiltrating glandular structures (A) with variable degrees of squamous differentiation (B,C) in a spindle cell background (D) entrapping
residual normal glands (C–E). Lymphocytic aggregates were present in all tumours (D–F).
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et al.3 have reported on the molecular karyotype
obtained in two cases of LGASC by microarray com-
parative genomic hybridisation, and have shown a
rather simple genome in one case and a higher
degree of complexity of copy number changes in the
other case, which harboured a focal EGFR amplifica-
tion. By means of chromogenic in-situ hybridisation
analysis, the authors were able to demonstrate that
the EGFR amplification found in the epithelial cells
was also present in a minority of the spindle cells of
the stromal component, in particular in those near
the epithelial clusters.
With the exception of the study above, the molecu-
lar underpinning of LGASC is largely unknown. The
advent of MPS has contributed to a thorough charac-
terisation of the genetic landscape of breast cancer.27
Recently, it has been demonstrated that, although
metaplastic carcinomas and common forms of TNBC
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Figure 2. Immunophenotype of glandular, squamous and spindle cell components. Median values of percentages of positive cells (grey bar
plots) within the glandular, squamous and spindle cell components are shown. Numbers of positive cases relative to the total number of
cases available for analysis per marker (the threshold for positivity was set at 10%) are indicated at the bottom of the columns.
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harbour similar mutational frequencies for TP53,
they are genetically distinct entities.19 Metaplastic
carcinomas show more frequent mutations in
PIK3CA, PIK3R1, PTEN (57% of cases), and Wnt
pathway genes (51% of cases). PIK3CA mutations are
significantly more frequently observed in spindle cell
metaplastic carcinomas than in other metaplastic car-
cinomas.19 In this context, our results provide
another piece of evidence for heterogeneity within the
spectrum of metaplastic carcinomas. We observed
that LGASCs seem to lack TP53 mutations and to
harbour a relatively high frequency of PIK3CA muta-
tions (52%), in stark contrast to high-grade spindle
cell metaplastic carcinomas, which harbour both
TP53 and PIK3CA mutations.
Recently Geyer et al.28,29 have reported on the exis-
tence of a ‘low-grade triple-negative breast neoplasia
family’ featuring microglandular adenosis/atypical
microglandular adenosis as non-obligate precursors of
TNBC, and acinic cell carcinomas as low-grade forms
of TNBC with the potential to transform into conven-
tional high-grade TNBCs. Both microglandular adeno-
sis/atypical microglandular adenosis associated with a
carcinoma and acinic cell carcinomas have been
shown to harbour TP53mutations, and the acquisition
of a TP53 mutation seems to represent the key event in
the possible progression of microglandular adenosis/
atypical microglandular adenosis to a carcinoma.29 In
this respect, the lack of TP53 mutations and the pres-
ence of PIK3CA mutations in LGASC may suggest that
these lesions follow a molecular evolutionary pathway
that is distinct from that of conventional TNBC. Inter-
estingly, lesions such as papillomas,30 RS/CSLs31,32
and infiltrating epitheliosis33 have also been shown to
harbour PIK3CA mutations, and the causative role of
PIK3CA mutations in these entities remains unclear.
As a further level of complexity, an association
between RS/CSLs and LGASCs has also been docu-
mented.24,34 In this scenario, one could hypothesise
that LGASC of the breast may represent an indolent
A B
C D
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Figure 3. Immunophenotypic profile of low-grade adenosquamous carcinomas of the breast (LGASCs). A, LGASC with glandular, squamous
and spindle components (Hematoxylin-Eosin-Saffron). B, LGASC is a triple-negative carcinoma showing cytokeratin (CK) 5/6 expression. C, The
spindle cells are positive for a-smooth muscle actin. D–F, The glandular and squamous components express CK14 (D), p63 (E), and EZH2 (F).
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carcinomatous lesion whose non-obligate precursor
may be identified in RS/CSLs, at least in a subgroup of
cases. To unravel the causative role within this associ-
ation, comparative molecular analyses of synchronous
RS/CSLs and LGASCs are warranted. At present, a sin-
gle report has documented a case with synchronous
CSL featuring infiltrating epitheliosis and an LGASC
that shared the same PIK3CA and SF3B1 mutations,
thus providing evidence that the LGASC most likely
originated from the CSL.33
Another low-grade variant of metaplastic carci-
noma, i.e. fibromatosis-like metaplastic carcinoma,
may arise in direct association with sclerosing papil-
lary lesions.34 Molecular studies dissecting the genetic
landscape of this lesion would be of help in ascertain-
ing whether or not these lesions share a genetic back-
ground with LGASC.
Our study has some limitations. The first is the lim-
ited number of cases analysed by MPS; nevertheless, it
has to be acknowledged that LGASC represents a rare
entity, and the major finding of the sequencing related
to PIK3CA mutations was validated in an independent
cohort. Second, the targeted panel used was composed
of a limited number of genes, and covered either hot-
spots or a limited number of exons. It is rather remark-
able, however, that none of the cases showed TP53
mutations, as this gene was fully covered in the
sequencing assay except for exon 1. Notwithstanding
this, we cannot exclude the possibility that more com-
prehensive analyses in larger series may add to the real
frequency of PIK3CA mutations, or unveil the presence
of TP53 mutations in a subgroup of cases and provide
evidence of additional recurrent mutations characteris-
ing this entity. Finally, four of the 13 patients were fol-
lowed up for <5 years, a time interval that may be
suboptimal for investigating the behaviour of a low-
grade form of invasive carcinoma of the breast. Never-
theless, no disease recurrence events were observed in
patients with longer follow-up.
However, even if we take these limitations into
account, our study not only confirms the morphologi-
cal and immunohistochemical data already reported in
the literature concerning this entity, but also provides
evidence suggesting that LGASCs constitute a distinct
genetic entity among metaplastic carcinomas, charac-
terised by high rates of PIK3CA mutations and a lack
of TP53 mutations, a triple-negative phenotype, and
no AR expression. Although further studies are needed
to confirm and expand our findings, this observation
seems to corroborate the concept that LGASC should
be distinguished from high-grade forms of metaplastic
carcinoma and other triple-negative/basal-like carcino-
mas that are associated with an aggressive behaviour.
At present, the clinical management of LGASC requires
complete local and regional treatment, including sur-
gery and radiotherapy. In our experience, axillary
lymph node dissection and adjuvant therapies do not
appear to be warranted, because of the favourable
prognosis of these cancers. Additional analyses are
required to assess the inflammatory stromal reaction in
terms of antitumour immunity. Finally, further studies
analysing the distinct cell components of LGASC are
warranted to gain insights into the neoplastic nature of
the spindle cells constituting the background of these
tumours.
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